查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1715804

基於人工智慧的臨床試驗市場：按組件、按人工智慧技術、按試驗階段、按部署模式、按治療領域、按應用和按最終用戶 - 2025-2030 年全球預測

AI-based Clinical Trials Market by Component, AI Technology, Study Phase, Deployment Mode, Therapeutic Area, Application, End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計 2024 年基於人工智慧的臨床試驗市場價值將達到 77.3 億美元，2025 年將達到 91.7 億美元，複合年成長率為 18.84%，到 2030 年將達到 217.9 億美元。

主要市場統計數據
基準年2024年 77.3億美元
預計2025年 91.7億美元
預測年份 2030 217.9億美元
複合年成長率（%） 18.84%

人工智慧與臨床研究的融合正在重塑醫療保健創新的格局。本報告檢驗了人工智慧技術如何透過提高數據準確性、最佳化患者招募和簡化研究設計來徹底改變臨床試驗。隨著醫學界接受這些進步，加速臨床試驗和降低成本的好處變得越來越明顯。借助強大的計算模型、預測分析和先進的監測技術，臨床研究的未來將比以往任何時候都更具創新性和有效性。

本介紹將深入探討影響當今臨床試驗的轉變，這是對世界各地的相關人員和決策者至關重要的議題。以下部分探討了人工智慧在臨床試驗中整合的關鍵市場區隔見解、區域趨勢和公司特定策略。該報告是一份綜合指南，旨在為行業領導者提供清晰、可行的建議，並為這個快速發展的領域的前沿人士提供資訊和啟發。

臨床研究數位轉型的時代不僅是一場進化，更是一場革命。人工智慧技術與研究方法的結合正在帶來切實的成果，從改善試驗結果到提高病患安全。未來幾天，我們將進一步闡明這項變化的意義及其對更廣泛的醫療保健生態系統的影響。

人工智慧推動臨床試驗格局的變革

近年來，臨床試驗生態系統發生了變革。先進演算法與臨床數據的融合為研究人員提供了前所未有的洞察力和預測能力。這些發展不僅縮短了測試時間，而且提高了結果的可靠性。

越來越多的公司採用基於人工智慧的監控系統和預測建模工具，以實現即時數據追蹤和強大的安全監控。這項技術進步與研究設計和實施中重新定義的決策方法結合。透過自動化和智慧數據管理減少手動任務，負責人現在可以專注於更高價值的活動，例如假設檢驗和進一步的科學探索。

此外，雲端基礎的解決方案和向內部部署基礎架構的遷移提供了靈活的部署模式，以滿足不同組織的需求。深度學習和機器學習模型的成熟，提高了診斷的準確性和治療的安全性，為臨床研究業務樹立了新的標竿。隨著法律規範不斷發展以適應這些技術進步，相關人員對整合人工智慧的長期利益越來越有信心。

這種轉變的影響是深遠的。相關人員不僅看到了效率的提高，而且看到了業務風險的顯著降低。先進人工智慧技術的採用為更具可擴展性、靈活性和適應性的臨床試驗鋪平了道路，確保醫療保健行業能夠應對新興的科學挑戰和患者需求。數位轉型時代標誌著現代研究能力的巔峰，並為更具創新性和更有效的調查方法提供了清晰的道路。

基於人工智慧的臨床試驗市場的關鍵細分洞察

對市場的詳細分析揭示了一個多方面的細分框架，該框架從幾個關鍵維度剖析了基於人工智慧的臨床試驗格局。市場主要按組件細分，重點是服務和軟體解決方案。在服務領域，這包括諮詢、資料管理、實施、維護和營運支援。在軟體方面，基於人工智慧的監控系統、數據管理平台和預測分析工具等創新正在製定新的行業標準。

此外，人工智慧分割技術揭示了電腦視覺、深度學習、機器學習和自然語言處理之間的複雜相互作用。每項技術都為市場做出了獨特的貢獻，提高了臨床數據的可靠性、提高了診斷的準確性並增強了整體臨床試驗的表現。將人工智慧技術融入傳統臨床試驗流程正在創建一個效率和準確性不再相互排斥的生態系統。

臨床試驗階段細分涵蓋了臨床試驗各個階段不斷變化的需求，從第 1 階段的早期評估到第 2 階段、第 3 階段和第 4 階段的更大規模試驗。每個測試階段都有特定的技術要求，確保 AI 解決方案能夠根據每個開發階段的獨特動態進行客製化。同時，市場對部署模式的考量區分了雲端基礎和內部部署的基礎設施，反映了相關人員不同的營運偏好和安全需求。

由於市場專注於循環系統、內分泌學、感染疾病、神經病學、腫瘤學等專業，因此對治療領域的分析可以提供進一步的見解。每個治療領域都有其自身的挑戰，而人工智慧技術正擴大被客製化以滿足與這些醫療領域相關的特定需求。與治療領域細分同時，應用領域考慮涵蓋數據分析和解釋、文件和合規性、患者招募和登記、預測模型、安全監測和試驗設計最佳化。在這裡，先進的演算法支援決策，同時降低風險並加快測試過程。

最後，按最終用戶細分，突顯了學術和研究機構、生物技術公司、受託研究機構、醫院和診所以及大型製藥公司等各種營業單位對基於人工智慧的技術的採用。在這兩種情況下，採用人工智慧不再只是一種選擇，而是一項策略必要事項，它將推動臨床試驗效率和成功率的顯著提高。這些細分見解提供了對基於人工智慧的臨床試驗市場中存在的細微複雜性和機會的全面了解。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 整合進階數據分析和人工智慧，提高臨床試驗效率和結果
      • 慢性病發病率不斷上升，臨床研究需要高效、可擴展的解決方案
      • 擴大使用穿戴式技術來產生即時數據，用於人工智慧臨床研究
    • 限制因素
      • 不同人工智慧平台之間的互通性問題阻礙了無縫資料共用和協作
    • 機會
      • 將人工智慧融入預測模型，預測生物醫學研究的趨勢與機會
      • 利用人工智慧加強臨床研究中的藥物警戒和主動風險評估
    • 任務
      • 在人體臨床試驗中使用人工智慧的倫理問題
  • 市場區隔分析
    • 組件：利用基於人工智慧的監控系統：確保試驗的完整性並加強合規性
    • 最終用戶：將人工智慧融入藥物開發平臺，提高臨床研究的準確性和效率
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

6. 人工智慧為基礎的臨床試驗市場（按組成部分）

  • 服務
    • 諮詢服務
    • 資料管理
    • 實施服務
    • 維護服務
    • 營運服務
  • 軟體解決方案
    • 基於人工智慧的監控系統
    • 資料管理系統
    • 預測分析工具

7. AI臨床試驗市場（按AI技術）

  • 電腦視覺
  • 深度學習
  • 機器學習
  • 自然語言處理

8. 人工智慧臨床試驗市場（依研究階段分類）

  • 第一階段
  • 第 2 階段
  • 第 3 階段
  • 第四階段

9. 人工智慧的臨床試驗市場（按部署模式）

  • 雲端基礎
  • 本地

第 10 章：基於人工智慧的臨床試驗市場（按治療領域）

  • 心臟病學
  • 內分泌學
  • 感染疾病
  • 神經病學
  • 腫瘤學

第 11 章基於人工智慧的臨床試驗市場（按應用）

  • 數據分析與解釋
  • 文件與合規性
  • 病患招募和入組
  • 預測模型
  • 安全監控
  • 測試設計最佳化

第 12 章。基於人工智慧的臨床試驗市場（按最終用戶）

  • 學術研究所
  • 生技公司
  • 合約研究組織（CRO）
  • 醫院和診所
  • 製藥公司

13. 美洲以人工智慧為基礎的臨床試驗市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

14. 亞太地區基於人工智慧的臨床試驗市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

15. 歐洲、中東和非洲基於人工智慧的臨床試驗市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第16章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • AiCure, LLC
  • Aiforia Technologies Oyj
  • Antidote Technologies, Inc.
  • Avantor, Inc.
  • BioAge Labs
  • BioSymetrics Inc.
  • Deep 6 AI Inc.
  • Envisagenics
  • Euretos Services BV
  • Exscientia PLC by Recursion Pharmaceuticals
  • Google LLC by Alphabet Inc.
  • Innoplexus AG
  • InSilico Medicine
  • Intel Corporation
  • International Business Machines Corporation
  • Koninklijke Philips NV
  • Median Technologies
  • Nuritas Limited
  • Pharmaceutical Pipeline Enhancement Strategies, LLC
  • Saama Technologies, Inc.
  • Selvita SA
  • Symplr Software Intermediate Holdings Inc.
  • Trials.ai, Inc. by ZS Associates, Inc.
  • Unlearn.AI, Inc.
Product Code: MRR-03559044807A

The AI-based Clinical Trials Market was valued at USD 7.73 billion in 2024 and is projected to grow to USD 9.17 billion in 2025, with a CAGR of 18.84%, reaching USD 21.79 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 7.73 billion
Estimated Year [2025] USD 9.17 billion
Forecast Year [2030] USD 21.79 billion
CAGR (%) 18.84%

The convergence of artificial intelligence and clinical research is reshaping the landscape of healthcare innovation. In this report, we examine how AI-powered technologies are revolutionizing clinical trials by enhancing data accuracy, optimizing patient recruitment, and streamlining trial design. As the medical community embraces these advances, the benefits of speedier trials and cost reductions are becoming increasingly evident. With robust computational models, predictive analytics, and advanced monitoring techniques, the future of clinical research is set to be more innovative and effective than ever before.

This introduction sets the stage for a deep dive into the transformative changes affecting clinical trials today-a subject of critical importance to stakeholders and decision-makers worldwide. In the following sections, we will explore key market segmentation insights, regional trends, and company-specific strategies that underline the integration of AI in clinical trials. With clear, actionable recommendations provided for industry leaders, this report is a comprehensive guide intended to inform and inspire those at the forefront of this rapidly evolving sector.

The era of digital transformation in clinical research is not merely an evolution-it is a revolution. The integration of AI technologies into the research process is delivering tangible results, from enhanced trial outcomes to improved patient safety. As we progress, the narrative will further articulate the importance of this shift and its implications for the broader healthcare ecosystem.

Transformative Shifts in the Clinical Trials Landscape Driven by AI

Recent years have witnessed transformative shifts in the clinical trial ecosystem, ignited primarily by AI-driven innovations. The fusion of advanced algorithms with clinical data has provided researchers with unprecedented insights and predictive capabilities. These developments are not only shortening trial durations but also enhancing the reliability of outcomes.

Companies are increasingly adopting AI-based monitoring systems and predictive modeling tools, which enable real-time data tracking and robust safety monitoring. This technological evolution is coupled with a redefined approach to decision-making in trial design and execution. By reducing manual intervention through automation and intelligent data management, researchers can now focus on higher-value activities like hypothesis testing and further scientific exploration.

Moreover, the transition toward cloud-based solutions and on-premise infrastructures offers flexible deployment modes that cater to diverse organizational needs. The maturity of deep learning and machine learning models has enhanced both diagnostic accuracy and therapeutic safety, setting a new benchmark in clinical research operations. As regulatory frameworks evolve to accommodate these technical advances, there is growing confidence among stakeholders regarding the long-term benefits of AI integration.

The impact of these shifts is profound. Stakeholders are observing not only enhanced efficiency but also a significant reduction in operational risks. The adoption of advanced AI technologies has paved the way for more scalable, agile, and adaptive clinical trials, ensuring that the healthcare industry remains responsive to both emerging scientific challenges and patient needs. This era of digital transformation represents the pinnacle of modern research capabilities, highlighting a clear path towards more innovative and effective trial methodologies.

Key Segmentation Insights into AI-Based Clinical Trials Market

An in-depth analysis of the market reveals a multifaceted segmentation framework that dissects the AI-based clinical trials landscape along several critical dimensions. The market is primarily divided by component, where the focus rests on services and software solutions. Within services, the continuum ranges from consulting, data management, and implementation to maintenance and operational support. On the software front, innovations such as AI-based monitoring systems, data management platforms, and predictive analytics tools are setting new industry standards.

Furthermore, the segmentation by AI technology uncovers an intricate interplay of computer vision, deep learning, machine learning, and natural language processing. Each of these technologies contributes uniquely to the market, enhancing the reliability of clinical data, improving diagnostic precision, and bolstering overall trial performance. The layering of AI technology on top of traditional clinical trial processes has created an ecosystem where efficiency and accuracy are no longer mutually exclusive.

The segmentation by study phase integrates the evolving needs of trials at various stages-ranging from early-phase assessments in Phase 1 to expansive studies in Phase 2, Phase 3, and Phase 4. Each study phase has specific technological requirements, ensuring that AI solutions are tailored to the unique dynamic of each development stage. Meanwhile, the examination of deployment modes in the market differentiates between cloud-based and on-premise infrastructures, reflecting the diverse operational preferences and security needs of stakeholders.

Analyzing the therapeutic area provides additional layers of insight as the market navigates specialized fields such as cardiology, endocrinology, infectious diseases, neurology, and oncology. As each therapeutic area brings its own set of challenges, AI technologies are increasingly tailored to address the particular needs associated with these medical disciplines. Alongside therapeutic segmentation, the examination of application areas spans data analysis and interpretation, documentation and compliance, patient recruitment and enrollment, predictive modeling, safety monitoring, and trial design optimization. Here, advanced algorithms support decision-making while mitigating risk and expediting the trial process.

Finally, the segmentation by end-users showcases the adoption of AI-based technologies across a spectrum of entities, including academic and research institutions, biotechnology companies, contract research organizations, hospitals and clinics, and leading pharmaceutical companies. In each case, the deployment of AI is not merely a choice but a strategic imperative that is driving tangible improvements in clinical trial efficiency and success rates. Together, these segmentation insights offer a comprehensive view that captures the nuanced complexities and opportunities present within the AI-based clinical trials market.

Based on Component, market is studied across Services and Software Solutions. The Services is further studied across Consulting Services, Data Management, Implementation Services, Maintenance Services, and Operational Services. The Software Solutions is further studied across AI-based Monitoring Systems, Data Management Systems, and Predictive Analytics Tools.

Based on AI Technology, market is studied across Computer Vision, Deep Learning, Machine Learning, and Natural Language Processing.

Based on Study Phase, market is studied across Phase 1, Phase 2, Phase 3, and Phase 4.

Based on Deployment Mode, market is studied across Cloud-based and On-premise.

Based on Therapeutic Area, market is studied across Cardiology, Endocrinology, Infectious Diseases, Neurology, and Oncology.

Based on Application, market is studied across Data Analysis & Interpretation, Documentation & Compliance, Patient Recruitment & Enrollment, Predictive Modeling, Safety Monitoring, and Trial Design Optimization.

Based on End-Users, market is studied across Academic & Research Institutions, Biotechnology Companies, Contract Research Organizations (CROs), Hospitals & Clinics, and Pharmaceutical Companies.

Key Regional Insights: A Global Perspective

The global landscape of AI-based clinical trials presents a dynamic and varied picture, with distinct regional trends and opportunities that underscore the breadth and depth of this emerging market. In the Americas, robust funding, a well-developed healthcare infrastructure, and progressive regulatory frameworks have paved the way for early adoption and widespread implementation of AI-driven technologies. This region is experiencing a surge in clinical trial activities powered by innovative applications of AI, particularly in enhancing patient recruitment processes and streamlining data analysis.

In contrast, the combined region of Europe, the Middle East, and Africa is witnessing tailored approaches that address both the continent's diverse healthcare needs and specific regulatory challenges. Within this region, nations are investing heavily in technological capabilities to not only modernize clinical trial processes but also ensure compliance with stringent data privacy laws. The interplay between cutting-edge AI applications and traditional clinical trial methodologies is fostering unique opportunities for collaboration and technological innovation.

The Asia-Pacific region emerges as a hotspot of rapid innovation and growth in the AI-based clinical trials market. Driven by a burgeoning biotech industry, significant governmental initiatives, and an extensive pool of technical talent, this region is at the forefront of integrating AI to accelerate clinical research. As these countries continue to invest in state-of-the-art research facilities and digital infrastructure, the potential for breakthrough advancements in the design and execution of clinical trials continues to rise exponentially.

Together, these regional insights highlight the importance of localized strategies while affirming that the AI revolution in clinical trials is a global phenomenon. With each region contributing unique strengths and facing distinct challenges, the collective impact is a robust and transformative global market poised for sustained growth and innovation.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights: Driving Industry Innovation

At the heart of the AI-based clinical trials ecosystem lie a number of forward-thinking companies that are pioneering innovative solutions and driving industry growth. Industry leaders such as AiCure, LLC and Aiforia Technologies Oyj are charting new territories by integrating advanced analytics with clinical data to enhance monitoring and safety outcomes. Companies like Antidote Technologies, Inc. and Avantor, Inc. have also made significant strides by infusing their operational frameworks with AI-centric methodologies.

Further innovation is being spearheaded by businesses like BioAge Labs and BioSymetrics Inc., which are leveraging AI to refine predictive models and optimize patient outcomes. Deep 6 AI Inc. and Envisagenics are at the cutting edge of deploying AI in trial design and data analytics, ensuring that clinical processes are both agile and rigorously science-based. The market benefits from the strategic insights of Euretos Services BV as well, while Exscientia PLC by Recursion Pharmaceuticals continues to push the boundaries of drug discovery and trial acceleration.

Tech giants like Google LLC by Alphabet Inc. and Intel Corporation provide the technological backbone necessary for the development of scalable, high-performance AI solutions. International Business Machines Corporation, Koninklijke Philips N.V., and Median Technologies have also made commendable contributions by integrating sophisticated software solutions that address diverse healthcare challenges. Companies such as Nuritas Limited, Pharmaceutical Pipeline Enhancement Strategies, LLC, Saama Technologies, Inc., Selvita S.A., and Symplr Software Intermediate Holdings Inc. enrich the market ecosystem by delivering comprehensive, secure, and effective trial platforms. Furthermore, the innovations coming from Trials.ai, Inc. by ZS Associates, Inc. and Unlearn.AI, Inc. reflect a vibrant environment where technology meets medical necessity, continually driving the evolution of clinical research into a new era of precision and efficiency.

These companies not only lead by example-they also push industry standards upward, setting benchmarks for quality and performance while catalyzing further adoption of AI in clinical research. Their collective efforts are instrumental in overcoming traditional challenges in clinical trials, fostering an environment of growth, collaboration, and technological prowess.

The report delves into recent significant developments in the AI-based Clinical Trials Market, highlighting leading vendors and their innovative profiles. These include AiCure, LLC, Aiforia Technologies Oyj, Antidote Technologies, Inc., Avantor, Inc., BioAge Labs, BioSymetrics Inc., Deep 6 AI Inc., Envisagenics, Euretos Services BV, Exscientia PLC by Recursion Pharmaceuticals, Google LLC by Alphabet Inc., Innoplexus AG, InSilico Medicine, Intel Corporation, International Business Machines Corporation, Koninklijke Philips N.V., Median Technologies, Nuritas Limited, Pharmaceutical Pipeline Enhancement Strategies, LLC, Saama Technologies, Inc., Selvita S.A., Symplr Software Intermediate Holdings Inc., Trials.ai, Inc. by ZS Associates, Inc., and Unlearn.AI, Inc.. Actionable Recommendations for Industry Leaders

Industry leaders and decision-makers seeking to navigate the complexities of AI integration in clinical trials must adopt a multifaceted strategy that leverages both technological and operational innovations. To capitalize on emerging opportunities, it is essential to foster strategic collaborations that bridge the gap between cutting-edge technology providers and healthcare professionals. The establishment of cross-disciplinary teams can facilitate the seamless integration of AI into existing clinical trial frameworks, ensuring that each phase of the study benefits from enhanced accuracy, efficiency, and compliance.

Investing in scalable cloud-based and on-premise deployments is another critical recommendation. Such investments provide the dual benefits of flexibility and security, allowing organizations to choose deployment models that best align with their operational needs. Furthermore, participating in pilot projects and early-adopter programs can provide valuable insights into the practical challenges and benefits of integrating AI solutions. This approach positions organizations to fine-tune processes and build robust frameworks that withstand the rigors of regulatory scrutiny.

Industry leaders must also prioritize continuous staff training and development in advanced analytics and AI applications. By cultivating a workforce equipped with the latest skills, organizations can ensure that they remain at the forefront of technological advancements. Additionally, fostering a culture of innovation by allocating dedicated R&D budgets helps in identifying emerging trends and swiftly adapting operational strategies.

Finally, establishing clear metrics for success is essential. These metrics should not only track the efficiency and cost-effectiveness of AI integrations but also measure improvements in patient outcomes and data integrity. Using these metrics, organizations can continuously monitor performance and make data-driven decisions that enhance both clinical trial efficiency and overall strategic direction. In effect, these recommendations offer a comprehensive blueprint for leveraging AI to achieve measurable improvements and sustained competitive advantage in the clinical trials arena.

Conclusion: Harnessing AI to Transform Clinical Trials

The integration of AI within the clinical trials landscape marks a pivotal moment in the evolution of healthcare research. As technological advancements continue to drive innovation, the traditional approaches to clinical trials are rapidly being redefined. Enhanced capabilities in data management, predictive analytics, and real-time monitoring are contributing significantly to the acceleration of trial processes, ensuring that life-saving therapies reach patients more swiftly and safely.

Throughout this report, we have explored the multifaceted dimensions of AI-based clinical trials-from market segmentation and regional trends to key insights on industry leaders and companies. The transformative shifts witnessed in this sector are a testament to the immense potential of AI to enhance accuracy, reduce operational risks, and streamline complex processes. With the technology landscape rapidly evolving, the future of clinical trials is poised for even more significant breakthroughs.

As our analysis indicates, the successful integration of AI is not just about deploying new technologies; it is about transforming organizational mindsets and operational frameworks. The synergy between innovative tools and strategic insights is driving a new era of efficiency and effectiveness in clinical research. This convergence of technology and healthcare offers an unprecedented opportunity to improve patient outcomes while fostering an ecosystem of innovation, collaboration, and growth.

In summary, the insights and actionable recommendations presented herein aim to equip industry leaders with the knowledge and strategies necessary to harness the full potential of AI. By embracing these advancements and aligning their initiatives with emerging best practices, stakeholders can significantly enhance both the impact and success rates of clinical trials. The future is bright for AI-driven clinical research, promising a safer, faster, and more efficient path toward groundbreaking healthcare solutions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. The integration of advanced data analytics and AI to enhance clinical trial efficiencies and outcomes
      • 5.1.1.2. Rising incidence of chronic diseases and the need for efficient, scalable solutions in clinical research
      • 5.1.1.3. Increased use of wearable technology generating real-time data for use in AI-driven clinical studies
    • 5.1.2. Restraints
      • 5.1.2.1. Interoperability issues with diverse AI platforms impede seamless data sharing and collaboration
    • 5.1.3. Opportunities
      • 5.1.3.1. AI integration in predictive modeling to anticipate biomedical research trends and opportunities
      • 5.1.3.2. Utilizing AI for enhanced pharmacovigilance and proactive risk assessment in clinical research
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical concerns around the use of artificial intelligence in human trials
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Component: Harnessing AI-based monitoring systems: safeguarding trial integrity and enhancing compliance
    • 5.2.2. End-Users: Integrating AI in drug development pipelines enhancing precision and efficiency in clinical research
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. AI-based Clinical Trials Market, by Component

  • 6.1. Introduction
  • 6.2. Services
    • 6.2.1. Consulting Services
    • 6.2.2. Data Management
    • 6.2.3. Implementation Services
    • 6.2.4. Maintenance Services
    • 6.2.5. Operational Services
  • 6.3. Software Solutions
    • 6.3.1. AI-based Monitoring Systems
    • 6.3.2. Data Management Systems
    • 6.3.3. Predictive Analytics Tools

7. AI-based Clinical Trials Market, by AI Technology

  • 7.1. Introduction
  • 7.2. Computer Vision
  • 7.3. Deep Learning
  • 7.4. Machine Learning
  • 7.5. Natural Language Processing

8. AI-based Clinical Trials Market, by Study Phase

  • 8.1. Introduction
  • 8.2. Phase 1
  • 8.3. Phase 2
  • 8.4. Phase 3
  • 8.5. Phase 4

9. AI-based Clinical Trials Market, by Deployment Mode

  • 9.1. Introduction
  • 9.2. Cloud-based
  • 9.3. On-premise

10. AI-based Clinical Trials Market, by Therapeutic Area

  • 10.1. Introduction
  • 10.2. Cardiology
  • 10.3. Endocrinology
  • 10.4. Infectious Diseases
  • 10.5. Neurology
  • 10.6. Oncology

11. AI-based Clinical Trials Market, by Application

  • 11.1. Introduction
  • 11.2. Data Analysis & Interpretation
  • 11.3. Documentation & Compliance
  • 11.4. Patient Recruitment & Enrollment
  • 11.5. Predictive Modeling
  • 11.6. Safety Monitoring
  • 11.7. Trial Design Optimization

12. AI-based Clinical Trials Market, by End-Users

  • 12.1. Introduction
  • 12.2. Academic & Research Institutions
  • 12.3. Biotechnology Companies
  • 12.4. Contract Research Organizations (CROs)
  • 12.5. Hospitals & Clinics
  • 12.6. Pharmaceutical Companies

13. Americas AI-based Clinical Trials Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific AI-based Clinical Trials Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa AI-based Clinical Trials Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Scenario Analysis
    • 16.3.1. Emmes Group collaborates with Miimansa AI to transform clinical trials with generative AI capabilities
    • 16.3.2. Healwell AI's acquisition of BioPharma Services enhances patient-centered clinical trials through AI integration
    • 16.3.3. Accenture's Strategic investment in QuantHealth to revolutionize AI-powered clinical trials
  • 16.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AiCure, LLC
  • 2. Aiforia Technologies Oyj
  • 3. Antidote Technologies, Inc.
  • 4. Avantor, Inc.
  • 5. BioAge Labs
  • 6. BioSymetrics Inc.
  • 7. Deep 6 AI Inc.
  • 8. Envisagenics
  • 9. Euretos Services BV
  • 10. Exscientia PLC by Recursion Pharmaceuticals
  • 11. Google LLC by Alphabet Inc.
  • 12. Innoplexus AG
  • 13. InSilico Medicine
  • 14. Intel Corporation
  • 15. International Business Machines Corporation
  • 16. Koninklijke Philips N.V.
  • 17. Median Technologies
  • 18. Nuritas Limited
  • 19. Pharmaceutical Pipeline Enhancement Strategies, LLC
  • 20. Saama Technologies, Inc.
  • 21. Selvita S.A.
  • 22. Symplr Software Intermediate Holdings Inc.
  • 23. Trials.ai, Inc. by ZS Associates, Inc.
  • 24. Unlearn.AI, Inc.

LIST OF FIGURES

  • FIGURE 1. AI-BASED CLINICAL TRIALS MARKET MULTI-CURRENCY
  • FIGURE 2. AI-BASED CLINICAL TRIALS MARKET MULTI-LANGUAGE
  • FIGURE 3. AI-BASED CLINICAL TRIALS MARKET RESEARCH PROCESS
  • FIGURE 4. AI-BASED CLINICAL TRIALS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY AI TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY AI TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY PHASE, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY PHASE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY DEPLOYMENT MODE, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY DEPLOYMENT MODE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USERS, 2024 VS 2030 (%)
  • FIGURE 21. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USERS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 25. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 27. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 29. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 30. AI-BASED CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 31. AI-BASED CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. AI-BASED CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AI-BASED CLINICAL TRIALS MARKET DYNAMICS
  • TABLE 7. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY DATA MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY IMPLEMENTATION SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY MAINTENANCE SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY OPERATIONAL SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY AI-BASED MONITORING SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY DATA MANAGEMENT SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PREDICTIVE ANALYTICS TOOLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY AI TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPUTER VISION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY DEEP LEARNING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY MACHINE LEARNING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY PHASE, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE 1, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE 2, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE 3, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE 4, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY CLOUD-BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY ON-PREMISE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY DATA ANALYSIS & INTERPRETATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY DOCUMENTATION & COMPLIANCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PATIENT RECRUITMENT & ENROLLMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PREDICTIVE MODELING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY SAFETY MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY AI TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY PHASE, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY AI TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY PHASE, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL AI-BASED CLINICAL TRIALS MARKET SIZE, BY AI TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL AI-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY PHASE, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL AI-BASED CLINICAL TRIALS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL AI-BASED CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA AI-BASED CLINICAL TRIALS MARKET SIZE, BY AI TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA AI-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY PHASE, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA AI-BASED CLINICAL TRIALS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA AI-BASED CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO AI-BASED CLINICAL TRIALS MARKET SIZE, BY AI TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO AI-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY PHASE, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO AI-BASED CLINICAL TRIALS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO AI-BASED CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY AI TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY PHASE, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY AI TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY PHASE, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 118. AUSTRALIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 120. AUSTRALIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY AI TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 122. AUSTRALIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY PHASE, 2018-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 124. AUSTRALIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. AUSTRALIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 127. CHINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 128. CHINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 129. CHINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 130. CHINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY AI TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 131. CHINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY PHASE, 2018-2030 (USD MILLION)
  • TABLE 132. CHINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 133. CHINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 134. CHINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. CHINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 136. INDIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 137. INDIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 138. INDIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 139. INDIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY AI TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. INDIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY PHASE, 2018-2030 (USD MILLION)
  • TABLE 141. INDIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 142. INDIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 143. INDIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. INDIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 145. INDONESIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 146. INDONESIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 147. INDONESIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 148. INDONESIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY AI TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 149. INDONESIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY PHASE, 2018-2030 (USD MILLION)
  • TABLE 150. INDONESIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 151. INDONESIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 152. INDONESIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. INDONESIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 154. JAPAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 155. JAPAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 156. JAPAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 157. JAPAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY AI TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 158. JAPAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY PHASE, 2018-2030 (USD MILLION)
  • TABLE 159. JAPAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 160. JAPAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 161. JAPAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. JAPAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 163. MALAYSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 164. MALAYSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 165. MALAYSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 166. MALAYSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY AI TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 167. MALAYSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY PHASE, 2018-2030 (USD MILLION)
  • TABLE 168. MALAYSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 169. MALAYSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 170. MALAYSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 171. MALAYSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 172. PHILIPPINES AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 173. PHILIPPINES AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 174. PHILIPPINES AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 175. PHILIPPINES AI-BASED CLINICAL TRIALS MARKET SIZE, BY AI TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 176. PHILIPPINES AI-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY PHASE, 2018-2030 (USD MILLION)
  • TABLE 177. PHILIPPINES AI-BASED CLINICAL TRIALS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 178. PHILIPPINES AI-BASED CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 179. PHILIPPINES AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. PHILIPPINES AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 181. SINGAPORE AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 182. SINGAPORE AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 183. SINGAPORE AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 184. SINGAPORE AI-BASED CLINICAL TRIALS MARKET SIZE, BY AI TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 185. SINGAPORE AI-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY PHASE, 2018-2030 (USD MILLION)
  • TABLE 186. SINGAPORE AI-BASED CLINICAL TRIALS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 187. SINGAPORE AI-BASED CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 188. SINGAPORE AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. SINGAPORE AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 190. SOUTH KOREA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 191. SOUTH KOREA AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 192. SOUTH KOREA AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 193. SOUTH KOREA AI-BASED CLINICAL TRIALS MARKET SIZE, BY AI TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 194. SOUTH KOREA AI-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY PHASE, 2018-2030 (USD MILLION)
  • TABLE 195. SOUTH KOREA AI-BASED CLINICAL TRIALS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 196. SOUTH KOREA AI-BASED CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 197. SOUTH KOREA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH KOREA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 199. TAIWAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 200. TAIWAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 201. TAIWAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 202. TAIWAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY AI TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 203. TAIWAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY PHASE, 2018-2030 (USD MILLION)
  • TABLE 204. TAIWAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 205. TAIWAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 206. TAIWAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 207. TAIWAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 208. THAILAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 209. THAILAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 210. THAILAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 211. THAILAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY AI TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 212. THAILAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY PHASE, 2018-2030 (USD MILLION)
  • TABLE 213. THAILAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 214. THAILAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 215. THAILAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 216. THAILAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 217. VIETNAM AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 218. VIETNAM AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 219. VIETNAM AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 220. VIETNAM AI-BASED CLINICAL TRIALS MARKET SIZE, BY AI TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 221. VIETNAM AI-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY PHASE, 2018-2030 (USD MILLION)
  • TABLE 222. VIETNAM AI-BASED CLINICAL TRIALS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 223. VIETNAM AI-BASED CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 224. VIETNAM AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 225. VIETNAM AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY AI TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY PHASE, 2018-2030 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 236. DENMARK AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 237. DENMARK AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 238. DENMARK AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 239. DENMARK AI-BASED CLINICAL TRIALS MARKET SIZE, BY AI TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 240. DENMARK AI-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY PHASE, 2018-2030 (USD MILLION)
  • TABLE 241. DENMARK AI-BASED CLINICAL TRIALS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 242. DENMARK AI-BASED CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 243. DENMARK AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 244. DENMARK AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 245. EGYPT AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 246. EGYPT AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 247. EGYPT AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 248. EGYPT AI-BASED CLINICAL TRIALS MARKET SIZE, BY AI TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 249. EGYPT AI-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY PHASE, 2018-2030 (USD MILLION)
  • TABLE 250. EGYPT AI-BASED CLINICAL TRIALS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 251. EGYPT AI-BASED CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 252. EGYPT AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 253. EGYPT AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 254. FINLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 255. FINLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 256. FINLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 257. FINLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY AI TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 258. FINLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY PHASE, 2018-2030 (USD MILLION)
  • TABLE 259. FINLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 260. FINLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 261. FINLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 262. FINLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 263. FRANCE AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 264. FRANCE AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 265. FRANCE AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 266. FRANCE AI-BASED CLINICAL TRIALS MARKET SIZE, BY AI TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 267. FRANCE AI-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY PHASE, 2018-2030 (USD MILLION)
  • TABLE 268. FRANCE AI-BASED CLINICAL TRIALS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 269. FRANCE AI-BASED CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 270. FRANCE AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 271. FRANCE AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 272. GERMANY AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 273. GERMANY AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 274. GERMANY AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 275. GERMANY AI-BASED CLINICAL TRIALS MARKET SIZE, BY AI TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 276. GERMANY AI-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY PHASE, 2018-2030 (USD MILLION)
  • TABLE 277. GERMANY AI-BASED CLINICAL TRIALS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 278. GERMANY AI-BASED CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 279. GERMANY AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 280. GERMANY AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 281. ISRAEL AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 282. ISRAEL AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 283. ISRAEL AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 284. ISRAEL AI-BASED CLINICAL TRIALS MARKET SIZE, BY AI TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 285. ISRAEL AI-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY PHASE, 2018-2030 (USD MILLION)
  • TABLE 286. ISRAEL AI-BASED CLINICAL TRIALS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 287. ISRAEL AI-BASED CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 288. ISRAEL AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 289. ISRAEL AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 290. ITALY AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 291. ITALY AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 292. ITALY AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 293. ITALY AI-BASED CLINICAL TRIALS MARKET SIZE, BY AI TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 294. ITALY AI-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY PHASE, 2018-2030 (USD MILLION)
  • TABLE 295. ITALY AI-BASED CLINICAL TRIALS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 296. ITALY AI-BASED CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 297. ITALY AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 298. ITALY AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 299. NETHERLANDS AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 300. NETHERLANDS AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 301. NETHERLANDS AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 302. NETHERLANDS AI-BASED CLINICAL TRIALS MARKET SIZE, BY AI TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 303. NETHERLANDS AI-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY PHASE, 2018-2030 (USD MILLION)
  • TABLE 304. NETHERLANDS AI-BASED CLINICAL TRIALS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 305. NETHERLANDS AI-BASED CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 306. NETHERLANDS AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 307. NETHERLANDS AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 308. NIGERIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 309. NIGERIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 310. NIGERIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 311. NIGERIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY AI TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 312. NIGERIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY PHASE, 2018-2030 (USD MILLION)
  • TABLE 313. NIGERIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 314. NIGERIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 315. NIGERIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 316. NIGERIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 317. NORWAY AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 318. NORWAY AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 319. NORWAY AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 320. NORWAY AI-BASED CLINICAL TRIALS MARKET SIZE, BY AI TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 321. NORWAY AI-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY PHASE, 2018-2030 (USD MILLION)
  • TABLE 322. NORWAY AI-BASED CLINICAL TRIALS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 323. NORWAY AI-BASED CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 324. NORWAY AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 325. NORWAY AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 326. POLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 327. POLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2030 (U